| Literature DB >> 22194790 |
Judith Beuving1, Annelies Verbon, Firza A Gronthoud, Ellen E Stobberingh, Petra F G Wolffs.
Abstract
BACKGROUND: Early administration of appropriate antibiotic therapy in bacteraemia patients dramatically reduces mortality. A new method for RApid Molecular Antibiotic Susceptibility Testing (RAMAST) that can be applied directly to positive blood cultures was developed and evaluated. METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2011 PMID: 22194790 PMCID: PMC3237415 DOI: 10.1371/journal.pone.0027689
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Tested antibioticsa and concentrationsb.
| Gram-positive panel | Gram-negative panel |
| AMX 0.25 mg/l | AMX 8 mg/l |
| AMX 8 mg/l | AMC 8/4 mg/l |
| OXA 2 mg/l | PIP 16 mg/l |
| VAN 2 mg/l | PIP 64 mg/l |
| VAN 4 mg/l | TZP 16/4 mg/l |
| GEN 4 mg/l | CIP 1 mg/l |
| STX 2/38 mg/l | CAZ 1 mg/l |
| CAZ 8 mg/l | |
| GEN 4 mg/l | |
| STX 2/38 mg/l | |
| Mixture of antibiotics | |
| Growth control (water) | |
AMX, amoxicillin; OXA, oxacillin; VAN, vancomycin; GEN, gentamicin; STX, sulfamethoxazole/trimethoprim; AMC, amoxicillin/clavulanate; PIP, piperacillin; TZP, piperacillin/tazobactam; CIP, ciprofloxacin; CAZ, ceftazidime;
These concentrations were based upon the CLSI breakpoints for susceptibility.
For Staphylococcus aureus.
For Enterococcus species.
For Enterobacteriaceae.
For Pseudomonas aeruginosa.
For non-fermenters.
For all strains.
Figure 1Growth kinetics of P. aeruginosa and S. aureus from blood cultures with and without antibiotics.
AMX, amoxicillin; OXA, oxacillin; VAN, vancomycin; CIP, ciprofloxacin; GEN, gentamicin; AMC, amoxicillin/clavulanic acid; PIP, piperacillin; TZP, piperacillin/tazobactam; CAZ, ceftazidim.
Tested isolates.
| Species | N |
|
|
|
|
| 19 |
|
| 7 |
|
| 3 |
|
|
|
|
| 49 |
|
| 11 |
|
| 7 |
|
| 7 |
|
| 2 |
|
| 2 |
|
| 1 |
|
| 1 |
|
| 1 |
|
| 1 |
|
| 1 |
|
| 1 |
Agreement and errors in the tested population, per antibiotic.
| Antibiotic | % Susceptible | % Agreement | No. minor errors | No. major errors | No. very major errors |
|
| |||||
| Amoxicillin | 36.8% | 89.5% | 0 | 0 | 2 |
| Gentamicin | 100% | 100% | 0 | 0 | 0 |
| Oxacillin | 100% | 100% | 0 | 0 | 0 |
| Trimethoprim/sulfamethoxazole | 100% | 100% | 0 | 0 | 0 |
| Vancomycin | 100% | 100% | 0 | 0 | 0 |
|
| |||||
| Amoxicillin | 30% | 95.0% | 0 | 1 | 0 |
| Vancomycin | 100% | 100% | 0 | 0 | 0 |
| Gram-negative rods (N = 85) | |||||
| Amoxicillin | 40.0% | 97.3% | 0 | 2 | 0 |
| Amoxicillin/clavulanate | 70.7% | 93.3% | 4 | 0 | 1 |
| Ceftazidime | 91.9% | 98.8% | 0 | 1 | 1 |
| Ciprofloxacin | 89.4% | 98.8% | 1 | 0 | 0 |
| Gentamicin | 94.1% | 100% | 0 | 0 | 0 |
| Piperacillin | 87.1% | 87.1% | 9 | 0 | 2 |
| Piperacillin/tazobactam | 97.3% | 100% | 0 | 0 | 0 |
| Trimethoprim/sulfamethoxazole | 71.8% | 96.5% | 0 | 3 | 0 |